Vir jumps after Phase 1 data for Sanofi-partnered cancer drug technology

_{//science-technology.news-articles.net/content/2 .. for-sanofi-partnered-cancer-drug-technology.html}
^{Published in Science and Technology on Wednesday, January 8th 2025 at 10:22 GMT by MSN}

Shares of Vir Biotechnology (CIR) climbed ~42% in the premarket on Wednesday after the company posted initial Phase 1 data for two antitumor agents developed using its PRO-XTEN masking technology, in-licensed from Sanofi (NASDAQ:SNY).

The article from MSN discusses Vir Biotechnology's significant stock price increase following the release of promising Phase 1 data for their cancer drug technology, developed in partnership with Sanofi. The drug, VIR-2482, targets the T cell immunoglobulin and mucin domain-3 (TIM-3) receptor, which is involved in immune response regulation. The preliminary results showed that VIR-2482 was well-tolerated and demonstrated biological activity, suggesting potential effectiveness in treating various cancers by enhancing the immune system's ability to fight tumors. This development has not only boosted investor confidence but also highlighted the potential of Vir's innovative approach in immunotherapy, leading to a surge in its stock value.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biochemistry/vir-jumps-after-phase-1-data-for-sanofi-partnered-cancer-drug-technology/ar-AA1xaULT ]